"2024 represents perhaps our biggest year yet in terms of three new drug approval submissions to the United States (U.S.) Food and Drug Administration (FDA) across our diagnostic portfolio: TLX250-CDx (Zircaix®) for kidney cancer, TLX101-CDx (Pixclara™) for glioblastoma and our “second generation” Prostate-specific membrane antigen (PSMA) imaging product for prostate cancer. Subject to regulatory review and approval, we are already preparing to launch and commercialise these products, following the success of Illuccix®. We have also remained steadfast to our goal of international expansion and the approval of Illuccix® and other products in ex-U.S. markets is anticipated."
Ann: Telix General Meeting Chairman and CEO Addresses, page-2
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.45 |
Change
-0.510(2.84%) |
Mkt cap ! $5.830B | |||
| Open | High | Low | Value | Volume |
| $17.90 | $18.13 | $17.25 | $23.78M | 1.358M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4746 | $17.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.46 | 979 | 1 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$17.53 |
Change
-0.510 ( 2.11 %) |
||||
| Open | High | Low | Volume | ||
| $17.99 | $18.12 | $17.26 | 233497 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| TLX (ASX) Chart |